Foundation Medicine: Priti Hegde
Priti Hegde has been appointed as CSO of Foundation Medicine, a Roche company, effective August 5. She replaces Michael Doherty, who will be retiring in September. Previously, she held various posts at Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Prior to that, she was manager of disease and biomarker transcriptomics at GlaxoSmithKline. Hegde holds a PhD in biochemical pharmacology from SUNY Buffalo and a B. Pharmacy degree from Mumbai University in India.
Oxford Nanopore Technologies: John Schoellerman
John Schoellerman has joined Oxford Nanopore Technologies as senior vice president of corporate development and investment. Previously, he was managing director and head of medtech at Lazard, and before that, he worked in healthcare investment banking at JP Morgan. Schoellerman holds a BA from Harvard University and an MBA from INSEAD.
Invitae: Randy Scott, Sean George
Invitae announced that Randy Scott will retire as executive chairman from its board of directors effective September 1. Invitae CEO Sean George will be the board's new chairman at that time. Scott served as CEO of Invitae between 2012 and 2017, after which George took over the reins. Scott said in a statement that he plans to continue to support the Invitae team as a private investor.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.